VIDA Diagnostics, a Coralville, Iowa-based medical imaging company, has announced a new distribution deal with TeraRecon, a leader in advanced visualization, artificial intelligence, image viewing, and post-processing. With this agreement, VIDA’s LungPrint analysis will be available through TeraRecon’s AI Interoperability platform, EnvoyAI, expanding the reach of VIDA’s leading AI-powered pulmonary care solutions and creating an integrated physician experience.

“VIDA is a valuable addition to our partner eco-system, offering physicians premium lung analysis and characterization AI with an integrated user experience that can only be achieved when interoperability is prioritized,” says Jeff Sorenson, President and CEO, TeraRecon. “Our customers have come to expect clinical workflow excellence for optimal patient care, and VIDA’s LungPrint solution brings another best-in-class application to our wide portfolio of AI algorithms available directly within our customers’ interpretation workflow,” he adds.

VIDA’s LungPrint Discovery offers fully automatic radiological metrics and unique, time-saving airway

VIDA and TeraRecon have a shared goal of equipping care teams with cutting-edge, clinically-validated AI solutions

visualizations. By precisely quantifying lung characteristics in a chest CT scan, LungPrint helps providers detect COPD and other interstitial lung diseases earlier, often when debilitating symptoms have yet to occur. Early detection of chronic lung disease is reported to elongate life expectancies and reduce overall healthcare costs. LungPrint also strengthens collaboration between radiologists and pulmonary clinicians, enhancing the content delivered in radiology reports and care team collaboration

“VIDA and TeraRecon have a shared goal of equipping care teams with cutting-edge, clinically-validated AI solutions,” says Susan A. Wood, President and CEO, VIDA. “We are excited to be partnering with TeraRecon; their AI platform elegantly integrates novel AI solutions like ours into the radiology workflow, which is a critical requirement in driving broad AI adoption in healthcare,” she adds.

LungPrint is an AI-powered imaging suite advancing pulmonary care by uniquely profiling the patient with or at risk of lung diseases, including interstitial lung diseases and COPD, which continues to be under-diagnosed. The solution grants providers access to important insights to better understand their patients’ set of conditions and to select the best care path to match those unique conditions.